Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Successful biologics must satisfy multiple properties including activity and particular physicochemical features that are globally defined as developability. These multiple properties must be simultaneously optimized in a very broad design space of protein sequences and buffer compositions. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of protein properties, increasing their activity and safety as well as decreasing their development time and manufacturing costs. We highlight the emerging applications of ML in biologics discovery and development, focusing on protein engineering, early biophysical screening, and formulation. We discuss the power of ML in extracting information from complex datasets and in reducing the necessary experimental effort to simultaneously achieve multiple quality targets. We finally anticipate possible future interventions of AI in several steps of the biological landscape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Unified rational protein engineering with sequence-based deep representation learning
Alley, E. C., Khimulya, G., Biswas, S., AlQuraishi, M., & Church, G. M. (2019) · Nature Methods · doi:10.1038/s41592-019-0598-1 · Cited by 1,131
Machine learning in chemoinformatics and drug discovery
Lo, Y.-C., Rensi, S. E., Torng, W., & Altman, R. B. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.010 · Cited by 960
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
Evaluating Protein Transfer Learning with TAPE
Rao, R., Bhattacharya, N., Thomas, N., Duan, Y., Chen, X., Canny, J., Abbeel, P., & Song, Y. S. (2019) · doi:10.1101/676825 · Cited by 719
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
Artificial intelligence for clinical trial design
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.005 · Cited by 672
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
In silico proof of principle of machine learning-based antibody design at unconstrained scale
Akbar, R., Robert, P. A., Weber, C. R., Widrich, M., Frank, R., Pavlović, M., Scheffer, L., Chernigovskaya, M., Snapkov, I., Slabodkin, A., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2031482 · Cited by 94
Persistent spectral theory-guided protein engineering
(2023) · doi:10.1038/s43588-022-00394-y · Cited by 62
Mutexa: A Computational Ecosystem for Intelligent Protein Engineering
Yang, Z. J., Shao, Q., Jiang, Y., Jurich, C., Ran, X., Juarez, R. J., Yan, B., Stull, S. L., Gollu, A., & Ding, N. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00602 · Cited by 28
AI-enabled alkaline-resistant evolution of protein to apply in mass production
Kang, L., Wu, B., Zhou, B., Tan, P., Kang, Y. (., Yan, Y., Zong, Y., Li, S., Liu, Z., & Hong, L. (2025) · eLife · doi:10.7554/elife.102788 · Cited by 7
AI-enabled alkaline-resistant evolution of protein to apply in mass production
Kang, L., Wu, B., Zhou, B., Tan, P., Kang, Y. (., Yan, Y., Zong, Y., Li, S., Liu, Z., & Hong, L. (2025) · eLife · doi:10.7554/elife.102788.3
Metadata
- Authors
- Narayanan, H., Dingfelder, F., Butté, A., Lorenzen, N., Sokolov, M., & Arosio, P.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 42
- Issue
- 3
- Pages
- 151-165
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W3125782153
- Cited by
- 145
- References
- 31
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.